Background: Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has a potent inhibitory effect against both T790M resistance mutations and EGFR-TKI sensitizing in EGFR, with a relatively low affinity for wild-type EGFR. Osimertinib has been approved as a therapeutic agent for patients with T790M-mutation positive advanced non-small cell lung cancer. As a firstline treatment, osimertinib may significantly prolong progression-free survival (PFS) in comparison with the earlier generation first-line standard treatment. Osimertinib has been reported to provide survival benefits to EGFR mutation-positive patients. However, the efficacy and safety of osimertinib as a first-line treatment for patients aged ≥75 years remains to be established.
Introduction
Due to population ageing, the incidence of lung cancer is increasing. The highest incidence rates of lung cancer in the US have been observed in the 80-89-year age group in men and 80-84-year age group in women (1) . Moreover, 14% of lung cancer patients in the US are aged ≥80 years (2) . In Japan, 45,000 individuals aged ≥75 years were estimated to have died of lung cancer in 2016 (3) . Thus, the development of a treatment strategy for elderly patients with NSCLC is an important issue.
Gefitinib, erlotinib are first-generation, and afatinib is a second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which have been approved for the treatment of EGFR mutation-positive advanced NSCLC. A meta-analysis of randomized control trials (RCTs) showed that EGFR-TKIs demonstrated a significantly longer median progression-free survival (PFS) than chemotherapy (11 versus 5.6 months) (4) . The third-generation EGFR-TKI, osimertinib, has been shown to have a potent inhibitory effect against both sensitizing mutations and resistance by T790M mutations in EGFR, with a relatively low affinity for wild-type EGFR. Osimertinib has been approved for patients with T790M mutation. As a first-line treatment, osimertinib significantly prolonged PFS in comparison with the standard EGFR-TKIs in the FLAURA study [18.9 versus 10.2 months; hazard ratio (HR): 0.46] (5) .
A phase II trial demonstrated that the efficacy of gefitinib is similar in younger (<75 years) and elderly (≥75 years) patients with EGFR-positive patients (6) . Osimertinib is well-tolerated compared with firstgeneration EGFR-TKIs (7) . The major adverse events observed in the FLAURA study were diarrhea (58% at all Grades, 2% at ≥ Grade 3) and acneiform rash (58% at all Grades, 1% at ≥ Grade 3) in the osimertinib group, and, in a similar manner, diarrhea (57% at all Grades, 2% at ≥ Grade 3) and acneiform rash (78% at all Grades, 7% at ≥ Grade 3) in the first-generation EGFR-TKIs group. The incidence of adverse events of ≥ Grade 3 was reported to be lower in the osimertinib group (33.7%) compared with the first-generation EGFR-TKIs group (44.8%) (5) .
Based on these findings, osimertinib is considered to potentially provide benefits to EGFR mutation-positive patients. In Japan, lung cancer clinical practice guidelines define patients aged ≥75 years as 'elderly'; furthermore, based on the results of some clinical studies in Japan, gefitinib and erlotinib are recommended in patients aged ≥75 years (6, 8) . Although a subset analysis of the data of patients aged ≥65 years was performed in the FLAURA trial, the data obtained for patients aged ≥75 years is highlighted in the elderly patients. In this study, we aim to investigate the efficacy and safety of osimertinib as a firstline treatment for EGFR mutation-positive NSCLC in patients aged ≥75 years.
Methods

Study design
This is a single arm, prospective, open-label, multicenter, phase II trial. The present study begun in November 2018 and is currently in progress.
End points
The primary endpoint is one-year progression-free survival (PFS). Secondary endpoints are response rate (RR), progression-free survival (PFS), overall survival (OS), and safety.
Eligibility criteria
The inclusion and exclusion criteria are shown in Table 1 .
Dose and treatment regimen
Osimertinib will be administered at a dose of 80 mg orally once daily, at the same time, with or without food. If a scheduled dose is missed, it will be recommended to take osimertinib as soon as possible; however, if it is less than 12 hours until the next scheduled dose, the missed dose of osimertinib will be omitted. Patients will continue to receive oral osimertinib until disease progression or until a discontinuation criterion ( Table 2) is met. A schema of the study is shown in Figure 1 .
Rationale for the setting of the number of enrolled subjects
In the FLAURA study, 1-year PFS for EGFR mutationpositive patients treated with osimertinib was approximately 70% and the median PFS was 18.9 months (5) . In addition, the 1-year PFS for EGFR mutation-positive elderly patients who received gefitinib in Japan was reported to be approximately 50% and the median PFS to be 12.1 months (6). Therefore, 37 patients are required for the present study, [10] Patients expected to survive for at least 3 months
[11] Patients who have completed a wash-out period for the prior treatment of at least the following duration as of the treatment initiation date (registration is allowed on and after the same day of the week as the day after the following period):
• Chemotherapy (preoperative/postoperative adjuvant chemotherapy): longer than 4 weeks after the last administration date
• Radiotherapy: definitive thoracic radiotherapy: longer than 12 weeks after the last radiation date • Other radiation therapy: longer than 2 weeks after the last radiation date when calculated based on normal approximation with a one-sided α level of 5% and 80% power, assuming that the expected 1-year PFS is 70% and the 1-year PFS threshold is 50%. Thus, to account for possible dropouts, the study sample size has been set to 40.
Population to be analyzed
Patients enrolled in this study, excluding those with serious protocol violation, will be included in the full analysis set (FAS). The per-protocol set (PPS) will include the remaining subjects from the FAS, after excluding those with violation of inclusion/exclusion criteria or violation for prohibited concomitant drugs/therapies. The safety analysis set (SAF) will include patients who received ≥1 dose of osimertinib.
Statistical analysis
The 1-year PFS will be estimated by the Kaplan-Meier method, and the confidence interval (CI) calculated using the Greenwood method. If the lower limit of the estimated 90% CI exceeds the threshold of 50%, it will be considered statistically significant. As for PFS and OS, the Kaplan-Meier method will be used to estimate the survival curve, median, and annual rate. The Brookmeyer and Crowley method will be used to estimate the median CI, and Greenwood's method will be used to estimate the standard error of the annual rate. The RR and 95% CI (two-sided) will be estimated via the Wilson method. The severity and incidence of each adverse event will be recorded.
Discussion
Osimertinib is expected to provide well-tolerated treatment for elderly EGFR mutation-positive patients with fewer serious adverse drug reactions and longer survival benefit compared with first and second generation EGFR-TKIs.
To our knowledge, this study is the first prospective trial to investigate the efficacy and safety of osimertinib as a firstline treatment for EGFR mutation-positive lung cancer in patients aged ≥75 years. [4] When the second dose reduction is required [5] When an adverse event requiring drug interruption for more than three weeks occurs [6] When a patient wants to withdraw from the protocol treatment [7] When a patient dies [8] When it becomes difficult for a patient to continuously receive medical consultations due to his/her move, transfer to another hospital or tight schedule
[9] When any reason arises to exclude the patient from the study following registration 
